Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

In this study (n=1032), there was no difference in overall survival between durvalumab and chemotherapy in the high PD-L1 population, or between durvalumab plus tremelimumab and chemotherapy in the intention-to-treat population.

Source:

The Lancet Oncology